36 articles - From Friday Oct 07 2022 to Friday Oct 14 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Arthritis Care Res (Hoboken) |
Prediction Models to Estimate The Future Risk of Osteoarthritis in the General Population: A Systematic Review. Despite growing interest in multivariable prediction models for incident OA, there remains a predominant focus on the knee, reliance on data from a small pool of appropriate cohort datasets, and concerns over general population applicability. |
RCT, clinical trials, retrospective studies, etc…
| Arthritis Care Res (Hoboken) |
Association between neighborhood deprivation and number of rheumatology providers. Rheumatologists tended to practice in areas with less deprivation, resulting in twice as many rheumatologists per 100,000 people in the quintile of lowest deprivation as opposed to the quintile with the highest deprivation. Public policy makers should be aware of these data and take steps to mitigate disparities in access to care as the rheumatology workforce shrinks. |
Effectiveness of a new service delivery model for management of knee osteoarthritis in primary care: a cluster randomised controlled trial. The PARTNER model improved knee pain and function more than usual GP care. The magnitude of improvement is unlikely to be clinically meaningful for pain but is uncertain for function. |
The Assessment of Systemic sclerosis-associated RAynaud's Phenomenon (ASRAP) questionnaire: Item Bank and Short Form Development. The ASRAP questionnaire has been developed with extensive SSc patient input, with items grounded in the lived experience of SSc-RP to ensure strong content validity, with a focus on how patients 'feel' and 'function'. An advanced psychometric approach with expert input has removed redundant and/or poorly fitting items, without eroding content validity. Long and short-form ASRAP questionnaires have been calibrated and scored to permit formal validation. |
Understanding the Impact and Tackling the Burden of Osteoarthritis for Aboriginal and Torres Strait Islander People. Our findings highlight that osteoarthritis is a multidimensional issue for Aboriginal and Torres Strait Islander people that permeates al aspects of life and highlights the need for integrated, multidisciplinary care that is culturally informed and individualized to patient need. |
| Arthritis Res Ther |
Comorbidity phenotypes and risk of mortality in patients with osteoarthritis in the UK: a latent class analysis. Opioid use and comorbidity clusters were differentially associated with the risk of mortality. The analyses may help shape the development of future interventions or health services that take into account the impact of these comorbidity clusters. |
Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study. We found new variants on chromosome 1 significantly relating to gout, and PRS predicts the risk of developing gout/AH more robustly based on the SNPs' effect types on the trait. |
Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. hep-mASCs showed higher anti-inflammatory and anti-fibrotic effects than mASCs alone and may be a promising candidate for SSc treatment. |
| Arthritis Rheumatol |
Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades-The Lupus Midwest Network (LUMEN). The incidence and prevalence of LN in this area increased in the last four decades. LN patients have poor outcomes with high rates of ESRD and mortality rates six times that of the general population. |
| Rheumatology (Oxford) |
"I turned in my man card": A qualitative study of the experiences, coping styles and support needs of men with systemic sclerosis. These novel data suggest SSc impacts male patients' masculine identity and roles, and although they will accept practical help, they may mask the full emotional impact. Sex and intimacy are important overlooked issues with erectile dysfunction often not discussed at diagnosis. Further research should develop a self-management intervention for men with rheumatic diseases with a combination of disease specific and common core components. |
Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis. TAMRA has proven utility in diagnosing GCA, and this data suggests that it also has utility in identifying alternative diagnoses to rule out the disease. Intracranial vasculitis was also seen in 14.3% of patients; the clinical impact of these findings is currently poorly understood and requires further study. |
Autoimmune activation and hypersensitization of the AT1 and ETA receptors contributes to vascular injury in scleroderma renal crisis. We provide experimental evidence that agonistic Abs may contribute to SRC. This effect is presumably related to direct receptor stimulation and additional allosteric effects, at least in heterodimeric receptor constellations. Novel therapies targeted at autoimmune hyperactivation of AT1R and ETAR might improve outcomes in severe cases of SRC. |
Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival. Additionally given MTX improves the effectiveness of biologic treatment in polyarticular JIA without seriously compromising treatment safety. Especially TNFi benefit from combination, while no improvement in outcome has been observed by combining tocilizumab with MTX. |
Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? In this review, we discuss the commonest comorbidities in the context of D2T RA. We propose the need for a paradigm shift in the clinical and research agenda for comorbidities- including a need to consider and manage these prior to the development of D2T disease and not as an afterthought. |
Favorable effect of a 'second hit' after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. Initial combination therapy was very successful in high-risk RA, and early intensification was beneficial in patients not reaching the strict target. The low-risk group was too small to draw conclusions. In routine practice, adherence to early intensification based on strict targets is difficult. |
Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome. Reactivity of functionally active anti-AT1R-antibodies was not influenced by aSCT, while anti-topo-I-antibodies decreased after aSCT. The fact that anti-topo-I antibodies inhibited enzyme function in al instances supports the hypothesis of a pathogenetic role of the topo-I antigen/antibody-system in SSc. High anti-topo-I reactivity before aSCT was associated with an unfavourable, presence of stimulatory anti-AT1R antibodies with a favourable course after aSCT. |
Nationwide racial/ethnic disparities in US emergency department visits and hospitalizations for gout. These first nationwide data found a substantial excess in both gout-primary ED visits and hospitalizations experienced by al underserved racial/ethnic groups, particularly by Black women, revealing an urgent need for improved care to eliminate inequities in gout outcomes. |
Revisiting idiopathic eosinophilic myositis: toward a clinical-pathological continuum from the muscle to the fascia and skin. The analysis of IEM and EF patient characteristics delineates 4 subgroups (FEM, DEM, EMF, and EF) in terms of clinical, laboratory, imaging, pathological, and outcome specificities and proposes an adapted diagnostic and care management approach. |
Similar effect of co-administration of methotrexate and folic acid for the treatment of arthritis compared to separate administration. Co-administration of MTX with FA on the same day did not reduce efficacy compared to FA application one day after MTX. Thus, co-administration of MTX and FA could be more convenient and improve compliance in patients. |
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD. This work also demonstrates that the management of SSc-ILD is highly variable among the different regions considered, suggesting that efforts are still needed for the standardisation of medical practice in the treatment of this disease. |
The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter? Treatment of active SpA also improves depressive symptoms. Especially in axSpA, TNFi have a larger effect than NSAIDs, which is mainly explained by a stronger effect on disease activity. We found no evidence for a direct link between CRP-mediated inflammation and depressive symptoms in SpA. |
The role of B cells in the pathogenesis of systemic sclerosis: an update. Ibrutinib, a Bruton's tyrosine kinase inhibitor, promoted B cells with low affinity for Topo I and decreased fibrosis. These findings provide a rationale for innovative B-cell-directed strategies, such as ibrutinib or chimeric antigen receptor T cells, particularly in the early inflammatory stage of the disease. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Ann Rheum Dis |
Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials? In this review, we will focus on phase II and III trials carried out with epratuzumab (anti CD22), baricitinib (Janus kinases inhibitor), rigerimod (P140 peptide) and ustekinumab (IL-12 and IL-23 inhibitor) and consider the reasons for their ultimate failure to 'make the grade'. Likewise, we will try to explain the possible reasons that can influence why good results may be obtained in phase II trials and lead to undue optimism. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Rheumatology (Oxford) |
Letters to the editors and authors’ replies
| Arthritis Care Res (Hoboken) |
| Arthritis Res Ther |
Absence of Epstein-Barr virus DNA in anti-citrullinated protein antibody-expressing B cells of patients with rheumatoid arthritis. These results do not support the hypothesis that EBV infection of autoreactive B cells causes or maintains autoreactive B cell populations in RA. Instead, other mechanisms might explain the association between positive EBV serology and RA. |
| Arthritis Rheumatol |